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Uterine leiomyomas are the commonest benign tumours in women of reproductive age.  
Fibroids have a significant impact on the woman’s quality of life as well as her fertility.  
Women who have symptomatic fibroids can present with abnormal uterine bleeding, pressure 
symptoms, pain, infertility, miscarriage or pregnancy complications.  This necessitates 
treatment.  There are many available options, apart from medical and surgical management, 
such as uterine artery embolisation.  This alternative to surgical treatment in an African 
population, who have a higher risk of fibroids, within a low resource setting is assessed in 
this study.  Uterine artery embolisation (UAE), is an interventional radiologic procedure that 
has developed over the last 10 years and is gaining popularity.  It involves occlusion of the 
uterine arteries thereby decreasing the blood supply to the fibroid, thus improving symptoms 
in patients.  The complications and outcomes of this procedure was assessed.   
 
Objectives and Methods 
The four objectives in this study were  
1. To describe the demographics of the women who have attended the Uterine Artery 
Embolisation clinic from January 2004 till December 2011. 
2. To describe the presenting complaints of the women attending Uterine Artery 
Embolisation clinic. 
3. To quantify the response of the fibroid to Uterine Artery Embolisation in terms of 
size.   
4. To document complications and outcomes associated with the procedure. 
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There were 100 women in the study sample ultimately who had UAE done after specific 
inclusion and exclusion criteria were met.  The procedure was performed by interventional 




The mean age of women in this study was 34.5 years. Thirty four women (46%) had never 
conceived. The mean gravidity was 1 but 57 women (70%) were nulliparous.  Pain was the 
most common symptom experienced, followed by menorrhagia.  Fibroids were located 
intramurally in 94% of cases.  Most patients experienced overall symptomatic relief at 
follow-up visits. 
The commonest complication immediately post-UAE was pain.  Post-embolisation syndrome 
occurred in 24% of women.  At follow-up visits PV discharge, pain and bleeding were 
complications present. 
Incidental outcomes which could be defined as adverse events were assessed post-UAE 
procedure in a total of 24 patients over the 5 follow-up visits, although the questionnaire 
applied to all the women who underwent UAE.  Two patients were discharged (8%), 8 
patients became amenorrhoeic (33%) and 5 patients became pregnant (21%).  Three patients 
were referred for hysterectomy (13%) and 5 patients for myomectomy (21%).   
The mean height of fundus (HOF)  at presentation of women in this study was 17.8cm and 
the final mean HOF after UAE was 12.5cm. There was a 5.3cm difference in the mean height 
of fundus after treatment which was statistically significant.  
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The mean area of the dominant fibroid at initial presentation was 109.8cm2 and at final visit 




Symptomatic fibroids occur more commonly in younger African women with more severe 
symptoms, that impact on quality of life and have a high disease burden, yet conservative 
treatment that preserves the uterus is a sought after alternative.  UAE provides a safe and 
effective alternative to invasive surgery. After the results shown in this study, patients, 
gynaecologists and interventional radiologists should be encouraged to use UAE as a 
modality for the conservative management of fibroids in suitable candidates. 
 
1. LITERATURE REVIEW 
 
Uterine leiomyomas, also referred to as fibroids, are the commonest benign tumours in 
women and are the most common tumour in women of reproductive age.1,3,4,5,7,9,12The  
symptoms caused by fibroids are often distressing and have a significant impact on the 
woman’s quality of life as well as her fertility.6The emphasis of conservative treatment in 
women of reproductive age is ideally to retain their childbearing ability while controlling the 
symptoms caused by fibroids, and minimising the risks of invasive surgery.  Fibroids can be 
asymptomatic or cause distressing symptoms such as abnormal uterine bleeding, pressure 
symptoms, pain, infertility, miscarriage and pregnancy complications.10Once symptoms are 





Leiomyomas are tumours of the smooth muscle cells of the myometrium of the uterus, with 
each fibroid arising independently.2,4The actual incidence of fibroids is difficult to assess as 
women are frequently asymptomatic and undiagnosed.2Between 40 – 50% of women over 35 
years of age may have asymptomatic fibroids with the peak incidence of diagnosis occurring 
in women between their 30s and 40s.1,3,4Clinically apparent fibroids occur in 20% of women 
of reproductive age but may be as many as 70% present in-uteri at hysterectomies and in 50% 
of post-mortem examinations.5,7Observational evidence in premenopausal women shows an 
increase in fibroids with age through reproductive years.2,9In women over the age of fifty and 
who are still menstruating, there is a 40% incidence of fibroids.15 
 
The Fibroid Growth Study showed each fibroid had its own growth rate. These findings are 
consistent with studies showing that fibroids are monoclonal in origin.11Clinical studies show 
that multiple fibroids in the same uterus are derived from individual myometrial cells. 
Race 
Women of African descent have a greater predilection for fibroids.1,2,3,4,5Black race has been 
identified as a risk factor.2Wise et al, maintains a 2 – 3 fold  increased incidence of uterine 
fibroids in black women, than in white women.8Higher rates of fibroids among black women 
are evident across all age groups, and it is not uncommon to encounter fibroids in black 
women younger than 30 years of age.9Further evidence points towards black women having 
larger and more symptomatic fibroids than white woman at the time of diagnosis.9Black 
women also have a greater propensity to more rapid fibroid growth and are more likely to 
have multiple fibroids.17,20It is however, uncommon for fibroids to occur in any race under 
the age of 20.   
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The black-white disparity in fibroid occurrence is not explained by an established risk factor, 
however it is evidenced that black women are affected disproportionately by this condition. 
In the study by Wise et al, the association between hair relaxer use and leiomyomata was 
prospectively evaluated in a large cohort of premenopausal women involved in the Black 
Women’s Health Study.  Hair relaxers have been used by millions of black women in the US, 
often for long periods of time. These hair products may contain hormonally active products 
such as phthalates, which can be absorbed by the skin or inhaled and have shown to have 
oestrogenic effects in cell models and experimental animals.  Hair relaxers can cause burns 
and lesions in the scalp allowing entry of hair constituents into the body.  Results of the study 
showed the incident rate of fibroids comparing ever with never use was significant and 
duration of use and number of burns were positively associated with the risk of uterine 
leiomyomata. The risk of leiomyomata was unrelated to age of first use or type of 
formulation.  This study raised the hypothesis that hair relaxer use is associated with an 
increased risk of uterine leiomyomata; however the possibility of increased genetic 
predisposition among African ancestry could also explain the observed association.8 
Obesity 
Obesity is a risk factor for developing fibroids.2,7The increased risk of developing 
endometrial cancer is thought to be due to the higher level of circulating oestrogens in obese 
women. Uterine fibroids are also thought to be influenced by oestrogens.  Obesity is a major 
health concern and may cause hyperoestrogenism.  Shikora et al assessed the relationship 
between obesity and uterine leiomyomata and the results suggested that symptomatic uterine 
fibroids may be another co-morbid disease state associated with obesity.10 
Higher body-mass indices (BMI) are found in our South African female population compared 
to those reported in other African countries.  In a sample of 7726 South African women, 
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black women had the highest prevalence of overweight and obesity (58.5%), followed by 
women of mixed ancestry (52%), white women (49.2%) and then Indian women (48.9%).  
BMI was also found to increase with age.36In the United States of America (USA) the 
prevalence of obesity is defined as a body mass index (BMI) ≥ 30 and is nearly twice as high 
in black women compared to white women therefore obesity may be a contributory cause of 
increased disease burden among black women.35As a result obesity combined with African 
race suggests a strong association for higher rates of fibroids in our population.  In the 
Ontario trial, there was an association between fibroids and being overweight or obese, with 
prevalence of fibroids in 35% of overweight women and in 17% of women who were obese.20 
Hormonal influences 
The exact aetiology of fibroids is unknown however risk factors have been identified.1 
Hormones are the strongest factor demonstrating a causal relationship.  Oestrogens act as a 
major promoter of growth as mentioned by Ezeama et al, who also showed progesterone 
stimulates growth-like factors.1There is increasing evidence that progesterone and 
progesterone receptors also have a major role in the growth and development of uterine 
fibroids.10The growth of fibroids during reproductive life when circulating oestrogen is 
maximal, suggests a hormonal influence, as well as in pregnancy which is also associated 
with an increase in blood supply.  Sex steroids act via receptors which are found in higher 
concentrations in fibroids.3Post-menopausally, myomas shrink or fibrose.  
Nulliparity 
Nulliparity is associated with uterine fibroids and parity decreases the risk of developing 
fibroids with the number of term pregnancies.1,3The relationship between the number of term 




A study from Nigeria reviewing case records of 117 patients with fibroids over 5 years 
showed that a high intake of red meat increased the incidence of fibroids.1 
Pelvic infection 
An increased risk of fibroids was also linked to a history of pelvic infections, with the risk of 
fibroids increasing with the number of infectious episodes.1 
Genetics 
There seems to be an increased familial incidence.4Uterine leiomyomas appear to have a 
genetic basis for their presence and growth.5Cytogenetic abnormalities occur in 50% of 
cases.3Abnormal gene expression of myomas suggest dysregulated differentiation and 
resemble the myometrium of pregnancy.5 
Malignant transformation is extremely rare.3,5 
The risk of developing fibroids decreases with long term contraceptive use as well as with 
smoking.2,3,7 
Diagnosis 
The gold standard of diagnosis is histological confirmation, however diagnosis with the use 
of ultrasound is clinically accepted and is the most suitable initial test as it is the least 
invasive and most cost effective investigation.2Magnetic Resonance Imaging (MRI) can be 
used but it is an expensive investigation. A bimanual examination is usually the first 
indication that a patient may have fibroids but other investigations need to be done to 
differentiate them from other masses of pelvic origin.  
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Fibroids found during myomectomy can be in multiple sites, but can also occur 
singularly.1,3Fibroids range in size, and the determining factor of the final size is 
unknown.3The consistency varies from hard and stony (calcified) to soft (cystic degeneration) 
but they are usually firm or rubbery. 
Clinical presentation 
Presentation is variable and symptoms relate to size, location and number of fibroids.  
Patients can present with menorrhagia or symptoms of anaemia, dysmenorrhoea, infertility, 
recurrent miscarriages, pressure symptoms or an abdominal mass.  A palpable mass is usually 
a late presentation; however in the study in Nnewi, Nigeria, this was the commonest 
presentation (67.7%), followed by menorrhagia (41.7%) and then infertility (30.1%).1Evans 
and Brunsell found pressure symptoms (34%) were the most frequent presenting symptom, 
followed by menorrhagia (30%), infertility (27%) and recurrent pregnancy loss 
(3%).2Abnormal uterine bleeding accounted for 30% of symptoms and was described as the 
most common and important clinical feature leading to iron deficiency anaemia as well as 
having associated dysmenorrhoea.6, 17 
Fertility and pregnancy 
There is a definite association between fibroids and difficulty in conceiving but the 
relationship between infertility and fibroids is still unclear and controversial.3,17Hillard 
quoted a study stating a 10% rate of pregnancy complications in women with fibroids. The 
risk of complications appears to be influenced by location and size.4Some studies show low 
pregnancy rates when the cavity is distorted by fibroids, affecting implantation, but Eldar-
Geva et al disputed this observation and concluded that pregnancy rates are affected by 
fibroids even when there is no distortion of the cavity.  Yet some women with fibroids 
conceive without difficulty.17 
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Spontaneous miscarriage rates due to fibroids are unknown – some authors suggest that they 
may be possibly twice as common compared with normal pregnancies.  Miscarriages occur 
40% more frequently, prior to a myomectomy compared to spontaneous miscarriages 
occurring in 20% of women after a myomectomy.6Pregnancy rates seem to have improved 
after myomectomy in many studies.17 
Management 
Various treatment options are available.  Expectant management is the treatment of choice in 
patients that are asymptomatic, where patients are followed up at intervals and growth of the 
fibroid is monitored.   
Medical treatment 
Medical options have been developed in the last 20 to 30 years and are available to treat 
symptoms, but are usually for short term use due to side effects.  Medical management is not 
curative; it is usually to tide patients over until menopause or until surgery.  It is also used 
preoperatively to shrink tumours as well as in patients who are surgically unfit.  
The medical agents used to control symptoms include gonadotrophin-releasing hormone 
(GnRH) agonists that lead to the down-regulation of the pituitary receptors and ultimately 
cause a decrease in gonadotrophin output and consequently in ovarian steroid output.3,5 
Although effective, long term use is limited due to bone density loss, reduction in breast size, 
vaginitis, sweating and hot flushes.10 Use is restricted to a maximum of 6 months.17 
Selective progesterone receptor modulators (SPRM) cause amenorrhoea without causing 
anovulation, having a direct effect on the endometrium.3,5SPRMs are characterised by a 
tissue-specific partial progesterone antagonistic effect.  The exact mechanism of action is still 
unclear.10The side-effect of this drug is endometrial thickening which limits its use to 3 or 4 
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months.  It is licensed as a preoperative treatment for fibroids.  Progestins produce a 
hypoestrogenic effect by inhibiting gonadotrophin secretion and oppressing ovarian function.   
The combined oral contraceptive pill is also prescribed and recently the levonorgestrel-
secreting intrauterine system is being used to treat menorrhagia, in uteri smaller than 12 
weeks in size and where there is no distortion of the uterine cavity, because of the high 
expulsion rate.3,17 
Surgical options 
Surgical options involve hysterectomy or myomectomy.  For just over a century since the 
treatment of leiomyoma came into practice, hysterectomy is still the commonest option for 
treatment and leiomyoma are still the leading indication for hysterectomy in the 
USA.3,7,8,9,,11,17,35According to the American College of Obstetrics and Gynecology (ACOG) 
fibroids were accountable for 33% of hysterectomies performed in the United States of 
America in 1994.5Hysterectomy remains the only cure.  Before the 20th century there was no 
effective treatment and death from this benign disease was not uncommon. Drs Kelly and 
Cullen, who worked together at the John Hopkins Hospital, gradually developed the 
technique of an abdominal hysterectomy that has been so successful in preventing and 
controlling intra-operative haemorrhage.  In 1907 they published the paper “Myomata of the 
Uterus”.7This major milestone eliminated the mortality from leiomyoma today, unfortunately 
the morbidity is still present. 
Myomectomy has become popular for women who want to preserve their fertility and their 
uterus.  Myomectomy is the surgical removal of fibroids that can be done via a laparotomy or 
using a laparoscopic approach or in specific cases (submucosal fibroids entering the 
endometrial cavity) hysteroscopically.   
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Laparotomy is preferred for larger fibroids.  Methods of removal of fibroids involve a linear 
or elliptic incision over the largest myoma.  The plane of cleavage is identified between the 
myoma and the myometrium.  Sharp dissection or blunt dissection is required to enucleate the 
myoma from its bed.  Ideally other myomas should be removed from the same incision, 
preferably anteriorly and avoiding the endometrial cavity.  Myomectomy is ideal in a solitary 
pedunculated fibroid.  However if there are multiple fibroids, it is a time consuming and 
difficult surgery, with a substantial risk of bleeding  as well as adhesion formation and there 
is a risk of recurrence of 15 to 30% at 5 years.2It may not be possible to remove all fibroids, 
nor will the operation prevent new fibroids from growing.  It also escalates the 
recommendation for pregnant patients to have an elective caesarean section after a 
myomectomy, because of an established risk of uterine rupture in later pregnancy as with any 
uterine surgery, however the exact magnitude of the associated risk remains uncertain and 
data to support this recommendation is limited.2 
There is a trend towards more conservative treatment of symptomatic fibroids and changing 
attitudes of women to uterine preservation and childbearing.  Thus minimal access surgery 
and non-surgical techniques with less morbidity must be evaluated.6 
Surgery in women with higher BMIs is often technically more challenging may be associated 
with more post-operative risks due to the risk profile accompanying adiposity. 
Other Interventions 
Myolysis is the in-situ destruction of tumours by heat, laser or cryotherapy. Advantages are 
ease and speed of procedure, minimal blood loss and rapid recovery.  However there is an 
unknown risk of recurrence and risk of prolonged vaginal bleeding.  Myolysis can cause 
pelvic adhesions and there may be a delay in reduction of uterine size.2 
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High-Intensity Focused Ultrasound (HIFU) therapy is a non-invasive modality.  It involves 
an extracorporeal source of focused high frequency ultrasonic energy that causes precise 
thermo-ablation of the pathological tissue.18Tissue is destroyed by coagulative necrosis.19 
Another recent method of therapy involves uterine artery embolisation (UAE), an 
interventional radiologic procedure that has developed over the last 10 years and is gaining 
popularity.  It involves occlusion of the uterine arteries thereby decreasing the blood supply 
to the uterus and ultimately to the fibroid.3,7 
Patients presenting with symptomatic fibroids in need of surgical management do not always 
have the access to surgery due to long waiting lists, sometimes averaging 6 months, 
especially in resource depleted public sector hospitals.  Medical treatment is also not always a 
suitable alternative either due to side effects of treatment, availability of the drugs and 
logistical difficulties for the patient.   
On discovering that there was an operational Uterine Artery Embolisation clinic at the at 
Chris Hani Baragwanath Academic hospital, I was encouraged to learn that this relatively 
new mode of treatment was available to our patients.  
Embolotherapy was first reported for use in 1970 for the control of haemorrhage.  In the 
1980s Phis and colleagues used it for postpartum haemorrhage.  In the early 1990s Ravina 
and co-workers began using embolotherapy as a preoperative measure to decrease intra-
operative blood loss during myomectomy.  Embolotherapy was done 24 hours prior to 
surgery, but in some cases, it was done a few days or weeks before the surgery and patients 
experienced such marked improvements in symptoms that many surgeries were cancelled and 
UAE became a primary curative procedure.12After Ravina published a paper suggesting the 
usefulness of UAE, this procedure has become reasonably widespread.17 
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In October 1993, Ravina suggested using arterial embolisation as an alternative to surgery in 
women over 35 years of age, who did not desire fertility and in whom major surgical 
treatment was indicated.  A small experimental study of 16 patients aged between the ages 34 
to 49 years with symptomatic fibroids was carried out and embolisation was offered as a 
palliative treatment in women with a high operative risk with a mean follow-up of 20 months. 
This study sought to investigate whether arterial embolisation of myomata might decrease or 
eliminate symptoms as an alternative to surgery; however it was not a randomised study.  The 
results showed that menorrhagia resolved in 9 out of 14 women, 12 out of 16 women had a 
20-80% reduction in fibroid volume after 3 months and 2 cases were unsuccessfully treated 
(1 was a submucosal fibroid that was expelled and the other case of  multiple interstitial and 
submucosal fibroids that later required a myomectomy).  The main consequence was pelvic 
pain approximately12-16 hours after the procedure with 14 out of the 16 women requiring 
analgesia.  The hospital stay did not exceed 36 hours.  Both uterine arteries needed 
embolisation, due to arterial anastomoses. Complete and lasting devascularisation was needed 
to prevent revascularisation.  In this series there were no technical complications.  In their 
experience UAE did not induce massive necrosis of the myoma and the decrease in volume 
of myoma were due to vascular changes and a decreased blood supply.12  
UAE can be done as a day procedure under sedation, after informed consent has been 
obtained and iodine allergy excluded.  Pre-procedural blood tests include a full blood count, 
coagulation screen and serum creatinine value.15,16Overnight admission may be necessary, 
but in the large multicentre Ontario Uterine Fibroid Embolisation Trial, 18% stayed longer 
than one night and 5% stayed longer than two nights.17 
The procedure originally done by Ravina is described later in the Methods section.  
Embolisation can be done with a variety of embolic agents, such as acrylic co-polymer beads 
(500 to 700ųm) that are infused under fluoroscopy until slow flow or stasis occurs and fibroid 
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vasculature is occluded or polyvinyl alcohol particles (300-500ųm) are injected into the 
vessel until blood flow ceases.13,14,17After completion of embolisation, a fragment of Spongel 
(absorbable sponge gel) is left in the trunk of the uterine artery to ensure stability of this 
devascularisation.12Supplemental metal coils have also been used by some radiologists.14The 
embolisation procedure generally lasts between 60 to 90 minutes, with procedure time 
currently averaging 61 minutes.12,14The irradiation to the woman associated with this 
procedure is negligible.12  
The National Institute for Clinical Excellence (2004) evidence on UAE shows it is safe for 
routine use and that there is symptomatic benefit in the majority of patients in the short term.  
However more evidence is required about the degree and duration of the benefits as well as 
effects on fertility.15 
The Royal College of Obstetrics and Gynaecology (RCOG) and American College of 
Obstetrics and Gynaecology (ACOG) recommend that UAE not be offered to women who 
wish to retain their fertility. 
Contraindications to UAE include pregnancy or menopause, active pelvic infection, contrast 
medium allergy, arterio-venous malformations, desire for future fertility, an undiagnosed 
mass, and suspicion of adenomyosis.  
Proving efficacy of UAE could make it a more feasible option than surgery, that deserves 
better “marketing” to our patients. 
In an article by Goldberg, Pennsylvania, UAE was reported as a primary treatment for 
fibroids since 1995, and has been used to treat > 50 000 women till 2005 when the article was 
written.  It is a safe and effective procedure in well selected patients.  It has the additional 
benefit of being a potentially outpatient procedure, avoiding theatre time, having minimal 
21 
 
blood loss and a short recovery time.  Spies et al found UAE improved heavy bleeding in 
90% and reduction of bulk-related symptoms in 91% of women respectively.  Another 
prospective study by Spies et al, found UAE and hysterectomy to have similar benefits in 
improving quality of life, but significantly fewer complications with UAE than those who had 
undergone surgery.  Spies concluded that UAE was safe and effective compared with 
hysterectomy, had fewer complications and was associated with a shorter hospital stay.13,17 
An article in The Wall Street Journal of 2004, titled “Hysterectomy alternative goes 
unmentioned to many women,” insinuated that gynaecologists choosing not to discuss the 
option of UAE were protecting their own financial interests or were unfamiliar with the 
procedure or lacked long term data on the treatment.  Further, because radiologists do not 
provide post-procedural care, the complications of UAE fall to the treating gynaecologists 
thereby causing reluctance to use this modality of treatment.13 
Symptom Relief & Quality of Life 
As in most studies, menorrhagia was controlled or improved.12In the Ontario trial there was a 
significant improvement in menorrhagia by 83% which was unrelated to the initial fibroid 
size or volume reduction after UAE.  Dysmenorrhoea, bulk symptoms/size and urinary 
frequency/urgency improved by 77%, 84% and 86% respectively. Patient satisfaction was 
significantly associated with the degree of improvement in menses.  
In a study of 200 patients Spies et al found that heavy menstrual bleeding improved by 87% 
at 3 months and in 90% at 1 year.  Bulk symptoms improved in 93% of patients at 3 months 
and in 91% of patients at 1 year.22 
Walker et al showed a satisfactory subjective improvement in menstrual flow and fibroid 
related symptoms 5 to 7 years post-UAE, demonstrating long term satisfaction was 
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sustained.21,28A long-term follow-up study by Scheurig-Muenkler et al, found that  symptom 
severity scores decreased and Health Related Quality of Life scores (HRQOL) increased, 
with a significant improvement compared with short term results. Symptom control ranged 
between 70 to 93%.26,27 
Most patients had improvement of symptoms in 3 months and persisted in most cases for 2 
years, thus stability of symptom improvement did not change over time.22 
UAE was the subject of a systematic review commissioned by the National Institute for 
Clinical Excellence (NICE).  Studies in the review indicated that there was a mean fibroid 
volume reduction between 45% to 70%, but these reductions did not correlate with change in 
symptoms.  Improvements in symptoms were reported in 62% to 95% of the women.15 
In the Ontario trial only 17% of women self-reported excellent health, with young women 
more likely to complain about poor health compared to older women.20Depending on size and 
location of the fibroid, 88% of women found it bothersome and were embarrassed by the 
appearance of pregnancy.  Almost all women reported heavy life impact, however the mean 
life impact score were significantly decreased after UAE and 91% of women expressed 
satisfaction with UAE treatment.14Thus patient satisfaction paralleled symptom relief.22  
Reassuringly, 86% of women who had UAE would recommend it to family or friends.29 
Complications 
In a long term follow-up study in Germany in 2011 involving 82 patients over a median of 
6.3 years (range 5 to 7.6 years), there were no major complications according to the Society 
of Interventional Radiology.27There was also a low periprocedural complication rate of 8.5% 
and serious complications were less than 1%.24The low rate of adverse events are consistent 
with many large multicentre trials, and major adverse events are significantly lower than after 
23 
 
surgical interventions.28In a study by Spies et al there were no complications in 90% of 
women.24 
Complications can be immediate or delayed. Immediate complications include post-
procedural vaginal discharge (21%), spotting(22%) and vaginal bleeding(32%).  The 
development of a haematoma at the site of catheterisation and damage to femoral artery have 
also been reported.17 
Delayed complications include hot flushes and mood swings in 30% of women.  Fibroid 
expulsion in 10% of women can cause pain.  Amenorrhoea may follow in 1% of women, 
either transiently or permanently.17 
Abdominal and/or pelvic pain is normal sequel of UAE but was reported as a complication by 
some authors.15,26,28The pain is as a result of fibroid ischemia.  The onset of pain is immediate 
and usually lasts about 12 hours.  The pain requires analgesia administration; most women 
experience abdominal pain and cramps that requires oral analgesia only.  Non-steroidal anti-
inflammatories (NSAIDs) usually suffice but in certain studies patient controlled intravenous 
morphine was administered.26,28This pain was significant enough for women to have 
reservations for a repeat procedure.14On examining the Fibroid Registry for Outcomes Data 
(FIBROID), Worthington-Kirsch et al found the commonest adverse event after discharge 
was inadequate pain relief that required additional hospital treatment in 2.4% of patients and 
the risk of extended hospital stay for post-procedure pain was of concern.30  
Post-embolisation syndrome (PES) is a recognised event that occurs in 30 to 50% of 
patients.5,28It is associated with leucocytosis, pyrexia, nausea, vomiting, malaise and 
occasionally severe abdominal pain due to cytokine release secondary to necrosis, in the 
absence of infection.5It can occur for a few hours to a few days.28These symptoms are 
thought to be an immune-mediated response occurring after embolisation of any solid organ.  
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In anticipation of this syndrome anti-emetics, anti-pyretics and anti-inflammatories should be 
administered routinely post-procedure to control it.17 
Vaginal discharge is a common and important complication, due to shedding of fibroid 
material into the endometrial cavity.  The cure would be hysteroscopic resection of dead 
fibroid material when the persistent discharge is a major problem.  In long term follow-up 
studies 48% of patients complained of a vaginal discharge post-UAE; some experienced it 
continuously and others cyclically.  In a study by Walker et al, 71% of women reported  it to 
be a major irritant and 5% thought it was major problem, 31% of women felt it was offensive 
and 19% said it interfered with their sex life.  Passage of fibroid material was reported in 29% 
of women and passage of a whole fibroid in 5%. This was usually associated with pain and 
bleeding and occurred around 6 weeks post-UAE.21Expulsion of fibroids occurred mostly 
when fibroids were located submucosally.  If partially infarcted fibroid material remains 
attached to myometrium then hysteroscopic resection or dilatation and curettage can be 
performed.  MRI can assist to visualise size of infracted fragment, degree of extrusion and 
extent of adherent tissue.28 
Late expulsion of a fibroid can occur up to a year later, in 2% to 8% of women and can be 
followed by pelvic infection and fever.15   
Serious infections occur in less than 1% of cases, but must be treated aggressively to avoid 
systemic infection and the need for hysterectomy.28Infection must be distinguished from PES 
and should the symptoms of PES last longer than 5 days, infection should be investigated.26 
Amenorrhoea 
Amenorrhoea can be viewed as either a complication or a successful outcome depending on 
the patient’s desire.  In older women it may be a treatment success but in younger women it is 
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a significant complication resulting from premature menopause and resulting in infertility.  If 
amenorrhoea develops in women over 45 years it is difficult to distinguish between natural 
menopause and early menopause induced after UAE. 
Most studies in which ovarian dysfunction occurred post-UAE resulting in amenorrhoea and 
an increase in follicle stimulating hormone (FSH), were in women over 45 years of age.  Data 
from the Embolization Versus Hysterectomy (EMMY) study confirmed that there is an 
increase in FSH associated with a decrease in anti-mullerian hormone (AMH) following both 
UAE and surgery, although the impact of age itself was not determined.16AMH is shown to 
decrease after UAE, consistent with damage to the ovarian reserve.  Pelvic vasculature is 
variable.  If embolic material inadvertently lodges in the ovarian vasculature during UAE, 
blood supply may be compromised and loss of follicles may result; this loss of oocytes may 
go undetected because women may still have normal menstrual patterns.30Absence of 
amenorrhoea or normal FSH levels may not reflect the effect of UAE on ovarian reserve.  If 
UAE can independently lead to a decrease in ovarian reserve, the effect may be diminished 
by youth as these effects are identified less frequently in younger women.29Thus in the above 
40 age group, when there are fewer oocytes remaining, ovarian failure is detected clinically, 
however younger women may have oocyte depletion but not menopause.30 
In the Ontario trial, amenorrhoea post-UAE was highly age-related, averaging from 3% in the 
under 40 years age group to 41% in women over 50 years.14Ovarian failure under the age of 
45 years was a rare event. 
In a long term follow-up study, in 2011 by Scheurig-Muenkler et al,  permanent amenorrhoea 
occurred in 8% of women with a mean age of 50 years.27Another review states a rate of 1% 
to 7% in over 40 year old women.26 
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In an article on the long term outcomes from the Fibroid Registry, 29% of patients became 
amenorrhoeic, 79% of which were over the age of 45 and only 6% under the age of 40.29It is 
unknown whether UAE precipitated menopause or if menses ceased independently.  
A review article published in 2013 addressed the dose reduction during UAE, to decrease 
exposure to ovaries, would be beneficial as ovaries are sensitive to radiation.  A digital flat 
panel system can significantly decrease radiation dose in comparison to digital subtraction 
angiography (DSA).26Flat panel detectors are a class of solid-state X-ray digital radiography 
devices where X-rays pass through the subject being imaged and strike the detectors.  DSA is 
a fluoroscopy technique used to visualise blood vessels using contrast medium, the pre-
contrast image is subtracted from the latter image. 
Ovarian dysfunction presenting with irregular menses or amenorrhoea as well as menopausal 
levels of FSH have been reported in some studies, ranging between 3% to 14%. Amenorrhoea 
following UAE was reported in 3% of women under 40 years and 41% of women over 50 
years in the NICE guidelines 2004.15A multicentre randomised controlled trial comparing 
uterine artery embolisation with surgical treatment (REST) evaluated and compared effects of 
UAE and ovary-sparing surgical treatment on ovarian function and menstrual characteristics 
and found no significant difference in rates of ovarian failure at 12 months between UAE and 
surgical patients.16The findings in women under 45 years showed no enhanced deterioration 
of function, however in women over 45 years there was an increase in ovarian failure.  
Although premature ovarian failure (POF) is a severe complication of UAE for fibroids, its 
occurrence is unusual when embolisation is performed for other indications, for example 






Off-target embolisation usually affects the ovaries, but can also affect other vascular supplies.  
If the vaginal artery is involved it can result in sexual dysfunction and or dyspareunia.28 
Labial necrosis can also occur following UAE.33 
Pregnancy 
Impact on subsequent fertility is not well characterised after UAE and remains 
contoversial.16,32In 3 studies involving 604 women, 4% reported pregnancies following UAE, 
however it was unclear how many women planned to conceive.15A single article documented 
that although a successful pregnancy can occur after UAE, it may affect myometrial integrity 
and may lead to uterine rupture during pregnancy.17 
Younger women are keener on having UAE rather than a hysterectomy, with the intention of 
preserving fertility, thus studies like the Ontario uterine fibroid trial did not exclude these 
women, but fully informed them of the uncertain effects of UAE on conception and 
successful pregnancy outcomes. In this study, 31% of women still expressed a desire for 
children. 
Walker et al suggested UAE be offered in women who were suffering fibroid-related 
infertility after a failed myomectomy.21 
A review by Memtsa et al, addressing complications of UAE, found that women can have 
successful pregnancies after UAE but evidence shows it is risky during the early stages of 
pregnancy.  There is accumulating evidence that women can and do conceive after UAE but 
because of the greater risk of pregnancy complications it is still a relative contraindication in 
the majority of facilities in women who desire fertility.28 
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One randomised controlled trial addressing fertility after UAE compared to myomectomy in 
the short term and suggested a higher likelihood of conceiving with myomectomy (77.5%) 
versus UAE (50%).28 
Fertility may be jeopardised if the off-target effect of UAE affects the ovary resulting in 
ovarian ischemia, depletion of ovarian follicles and risk of premature menopause.28 
In observational studies the risk of miscarriage after UAE varied from 18% to 64% for 
spontaneous miscarriage, with a cumulative risk of 35%.  This was three fold higher than the 
entire population.  However in another series by Homer et al, where the risk of miscarriage 
after UAE was compared to the risk of miscarriage in a pregnancy complicated by fibroids, 
the risk was 35% compared to 16%. This data was contrary to what was expected, where 
treatment of fibroids should reduce the risk of miscarriage, however it did not and the reason 
is unknown.28 
Data collected from 200 pregnancies after UAE on outcomes were analysed and compared to 
women with untreated fibroids. Higher rates of preterm delivery, fetal growth restriction, 
fetal malpresentation as well as increased caesarean section rates were found, as well as 
increased incidence of post-partum haemorrhage were found in the women who had 
undergone UAE.28Similar pregnancy outcomes were illustrated in a study of 50 patients who 
conceived after UAE.32 
Recurrence risk 
The risk of fibroid recurrence is present after UAE and patients should be made aware of the 




Although the NICE guidelines deem UAE safe for routine use, recommendations for 
clinicians undertaking this procedure include taking informed consent and educating patients 
of the uncertainty of the degree and duration of the procedure’s benefits and the involvement 
of a multidisciplinary team.  Interestingly enough and relevant to my study, the NICE 
institute acknowledges that upon publication of further evidence this procedure may be 
reviewed by the institute.15 
Re-intervention 
Treatment failure can be multifactorial.  Inadequate fibroid infarction and regrowth due to 
incomplete embolisation or collateral blood flow can result in UAE failure.21 
Walker et al found 16% of women underwent other procedures since UAE.21Scheurig-
Muenkler et al found, in their long term prospective cohort study, with a 6.3 median year 
follow-up, there was a 17% treatment failure rate that required secondary intervention.  This 
was an acceptable failure rate after long-term follow-up.  Up to 29% of patients had 
recurrence with subsequent surgery or repeat endovascular intervention.27In a review by 
Memtsa et al, recurrence rates averaged 20% at 5 years however the REST and EMMY trial 
indicate an even higher rate of re-intervention, compared to other long term data, of 28.4% 
and 32% respectively.23,28 
Spies et al found gynaecological interventions occurred less frequently in 10.5% of patients.  
These involved hysteroscopic resection and dilatation & curettage.22 
In a large study involving 2112 patients over 3 years the long term outcomes from the 
FIBROID registry were assessed.  Further intervention was needed in 14.4% of patients.  
Repeated UAE was required in 1.8% of patients, hysterectomy in 9.8% of patients and 
myomectomy in 2.8% of patients.29 
30 
 
If a patient is under-embolised, a second UAE may result in success that may decrease the 
rate of surgical intervention.21 
Techniques to improve embolisation have been modified and MRI use in some studies have 
been implemented to confirm totality of fibroid infarction.21 
Surgical Intervention 
Although patients may need a hysterectomy after UAE, it may not always reflect a failure of 
UAE, but rather after shrinkage of a fibroid post-UAE; surgery may prove easier and 
successful.21 
Fibroid size and shrinkage 
In the Ontario trial fibroid reduction was found to have a greater percentage volume reduction 
after UAE, with the mean percentage volume reduction in larger fibroids being twice that of 
smaller fibroids.  The degree of uterine volume reduction was significant relative to baseline 
size.14  
In the Ontario trial there was a 42% reduction in mean dominant fibroid volume.  However 
the response of patients to volume reduction was variable.14Studies show that even beyond 6 
months continued reduction and shrinkage occurs.  Patients with bulk symptoms achieve 
significant reduction between 40 to 69% in uterine volume.17 
A study in Japan involving 25 patients, showed a 67.9% volume reduction at six months on 
ultrasound or MRI.  At 24 months follow-up, 96% of patients had improvement in symptoms 
and/or decrease in fibroid size.23Of note, the Japanese study demonstrated that UAE done in a 
woman with a solitary fibroid of more than 10cm or multiple fibroids in a uterus compared to 
a pregnancy of more than 20 weeks, was ineffective.23Data from the long term outcomes 
from the FIBROID registry found patients with smaller fibroids had better results.29 
31 
 
Of note, in the FIBROID registry, symptoms and the severity of symptoms did not correlate 
with objective measures of uterine and fibroid size.29 
Spies et al demonstrated the mean fibroid volume decreased by 44% at 3 months and 58% 
after 12 months, and this was sustained at 1 year post-treatment.22 
 
2.  PROBLEM STATEMENT 
Fibroids are a common gynaecological morbidity as described above, that impacts female 
health and wellbeing.  Definitive cure involves major surgery with its associated 
complications, time off work and a long recovery period.  An alternate treatment such as 
UAE has offered a cheaper, potentially safer and comparably effective alternative to other 
existing modalities.      
Chris Hani Baragwanath Academic Hospital has a UAE unit that has been in existence since 
2004.   
The aim of this study was to describe the success in managing troublesome symptoms of 











1. To describe the demographics of the women who have attended the Uterine Artery 
Embolisation clinic from January 2004 till December 2011. 
 
2. To describe the presenting complaints of the women attending Uterine Artery 
Embolisation clinic. 
 
3. To quantify the response of the fibroid to Uterine Artery Embolisation in terms of 
size.   
 
4. To document complications and outcomes associated with the procedure. 
 
 
4.  METHODS 
4.1 SETTING 
This study was conducted at Chris Hani Baragwanath Academic Hospital (CHBAH), a 
regional/tertiary academic hospital in South Africa, located in the south west of 
Johannesburg. This facility provides services to a low income socio-economic group. 
The study was conducted using data from the UAE clinic, one of several specialised 
gynaecological clinics which has been in existence since 2004.  Patients who are referred to 





4.2 STUDY POPULATION 
All patients attending the UAE clinic who had the procedure done at CHBAH since the 
inception of the clinic in 2004 till 2011 were included in the study.   
Patient selection was based on the following criteria: 
Women 
· who wished to retain their uteri 
· who were unsuitable for major surgery  
· in whom medical management had failed or who could not tolerate the side effects of 
medical treatment or where medical treatment was contraindicated or where a 
recommended drug was not available in the public sector 
· with uterine size larger than 14 weeks  
· with symptomatic fibroids   
 
Exclusion criteria  
· patient refusal for UAE 
· allergy to the contrast 
· patient who wanted to retain fertility 
· submucosal or pedunculated fibroids 
· pregnancy 
· post-menopausal women 
· bleeding diathesis 
· pre-existing renal disease 




Information obtained from the radiologists at CHBAH via personal communication described 
the procedure as follows.  Unilateral (usually right) femoral artery catheterisation is done and 
angiography of the aorto-iliac arteries to the pelvic arteries is performed, to identify the 
anatomy of the uterine arteries and visualise tumour hypervascularisation.  Angiography is 
followed by successive selective catheterisation of the right and left uterine arteries, generally 
with an in-situ catheter.  After positioning the catheter in the uterine artery, inert particles of 
Ivalon® in free flow are introduced; these particles are gradually increased in size until 
tumour blood flow is eliminated using polyvinyl alcohol particles (500 -700ųm). 
4.4 SAMPLE SIZE  
All patients who attended the clinic constituted the sample size.  All case notes of women 
referred were assessed and noted but only those who had UAE procedure done were included 
in the study.  
4.5 STUDY DESIGN AND DATA COLLECTION 
This was a longitudinal descriptive study where the data was collected retrospectively.  I 
accessed data retrospectively even though data was collected by clinicians prospectively 
when the patients presented.  Data was accessed from specific UAE clinic records, not from 
the patient’s original hospital files.  Blood results were accessed from the National Health 
Laboratory Service computers. 
4.6 CONTROL GROUP 
A control group was not utilised in this study because this study was not comparing UAE to 
any other treatment modality, but rather focussed on outcomes specific to this treatment. 
Patients who had hysterectomies constitute an inappropriate control. Ideally comparisons 
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should be made with patients who received medical treatment however we do not use these 
drugs routinely and thus such a control group would have been difficult to find. 
4.7 RECRUITMANT PROCEDURE 
Once the patient had been referred to the UAE Clinic and was found to be eligible for 
treatment, a detailed history was taken and an abdominal and pelvic examination was 
performed.  Ultrasonography using a Toshiba Ultrasound machine (model number 
CCISN71MA) was performed to confirm the presence of fibroids, exclude other pelvic 
pathology (e.g. adnexal masses) and the dimensions of the largest fibroid were measured.  
Patients were enrolled and information recorded onto a specifically designed data sheet for 
the clinic. 
Informed consent was taken, pre-procedural bloods including a haemoglobin and platelet 
value, urea and creatinine value as well as an international normalised ratio were drawn and 
the patient was given a date to return for UAE by the radiology department.  A week after the 
procedure the patient was instructed to return to the UAE clinic. 
If the patient suffered from any complications post-procedure, she was admitted to the 
gynaecology ward for observation and treatment.   
The protocol as per the UAE clinic involved follow-up at the following periods: between 2 
to11 weeks, 3 to 5 months, 6 to 11 months, 12 to 23 months and finally at 24 months or more.  
4.8 DATA ANALYSIS 
Data was collected on a data sheet specifically designed for this study.  It was entered onto a 
Microsoft Excel spread sheet and then cleaned.  The values were exported into a statistical 
software package (STATA 11).  Continuous variables were described using means and 
36 
 
standard deviations and medians with ranges.  Analytical statistics were used.  The Wilcoxon 
signed-rank test for paired non-parametric numeric variables, was used specifically the height 
of fundus and the paired t-test was used for the uterine size.  Statistical significance was 
accepted where p<0.05.   
4.9 ETHICS 
Patient confidentiality was maintained.  Each patient was assigned a study number and no 
identifiers were recorded on the data sheet.   
An application was submitted to the Human Research Ethic Committee (Medical) and to the 
hospital authorities for permission to do the study.  Permission was obtained from the 
relevant hospital authorities and unconditionally approval was given by the Human Research 
Ethic Committee (Medical).  Clearance certificate number is M140213. 
4.10 FUNDING 










5.     RESULTS 
5.1  DESCRIPTION OF RESULTS 
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Women who were assessed and had UAE done but whose follow up fell beyond the study 
period were not included and amounted to 6 patients.  
 







20 – 24 5 5.4 
25 - 29  17 18.3 
30 – 34 24 25.8 
35 – 39 30 32.3 
40 – 44 12 12.9 








The mean age of women in the study was 34.5 years (SD ± 6.0), with the maximum number 
of affected patients falling into the 35-39 year age group. There were 17 women (18.3%) 
between the ages of 25 to 29 who underwent UAE.  The youngest patient was 20 years old 














0 57 70.4 
1 14 17.3 
2 8 9.9 
3 1 1.2 








Women who were ever pregnant constituted 40 women (54%) and the remaining 34 women 
(46%) had never conceived.  A total of 19 miscarriages had occurred, 4 women (6.4%)  had 1 
miscarriage, 3 women (4.8%) had 2 miscarriages and 3 women (4.8%) had 3 miscarriages.  
Twenty women (27%) had conceived once, with one woman having had 5 pregnancies 
(1.4%) and 1 woman having had 4 pregnancies (1.4%). The mean gravidity was 1. In my 
study 57 (70.4%) women were nulliparous and 14 (17.3%) women had one child.   However 
one woman (1.2%)  had the highest parity which was 4 and one woman (1.2%) had a parity 






Table 3: Number and percentage of common presenting symptoms in women 





Menorrhagia 78 85.7 
Pain 77 90.6 
Dyspareunia 22 55.0 
Frequency 17 29.5 
Constipation 8 21.1 
  
Pain was the most common symptom experienced by women in my study, occurring in 
90.6% of patients, which was 78 women out of 91, followed by menorrhagia in 85.7%, which 
was 77 women out of 85. Pressure symptoms occurred less commonly, with 17 (29.5%) 
women experiencing urinary frequency and 8 (21.1%) women experiencing constipation. 
 





Submucosal 1 3.0 
Intramural 31 93.9 









On ultrasound, fibroids were located most frequently intramurally in the women in my study.  
In women with more than one fibroid on ultrasound, only the dominant fibroid was measured 
in this study. 
 
Table 5: Haemoglobin (Hb) levels in study participants prior to UAE procedure 






6 - 6.9 1 1.1 
7 - 7.9 7 7.6 
8 - 8.9 7 7.6 
9 - 9.9 12 13.0 
10 - 10.9 17 18.5 
11 - 11.9 15 16.3 
12 - 12.9 13 14.1 
13 - 13.9 16 17.4 
14 - 14.9 3 3.3 








The mean pre-procedural haemoglobin level in women participating in my study was 
11.1g/dL (SD ±2.0).  The lowest haemoglobin level was 6.5g/dL and the highest 15.8g/dL.  
Eight women had no pre-procedural haemoglobin level taken according to laboratory records. 
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Table 6: Haemoglobin (Hb) levels in study participants subsequent to UAE procedure 






4 - 4.9 1 3.3 
5 - 5.9 0 0 
6 - 6.9 0 0 
7 - 7.9 2 6.7 
8 - 8.9 5 16.7 
9 - 9.9 4 13.3 
10 - 10.9 3 10.0 
11 - 11.9 5 16.7 
12 - 12.9 3 10.0 
13 - 13.9 5 16.7 
14 - 14.9 1 3.3 








The mean post-procedural haemoglobin level in women participating in my study was 
10.7g/dL (SD ±2.5).  The lowest haemoglobin level was 4.3g/dL and the highest 15.3g/dL.  












Single 45 83.3 








Of note nine (16.7%) patients needed a double puncture of the femoral artery during UAE.  
There were 46 patients whose puncture sites were not recorded. 
 





Success 50 89.3 








In the 56 patients where success or failure was specified, 89.3% were deemed successful and 
10.7% failed.  Although the UAE procedure failed in 6 patients, these women were still 
included in the study because even though the procedure may not have been successful it was 
still performed, and it had to be acknowledged that some patients do undergo UAE and it 
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may be unsuccessful.  In such cases UAE can be attempted at a later stage.  Technical failure 
is a possibility thus it must be accounted for. 
 
Table 9: Duration of vaginal bleeding experienced by study participants in days 




2 to 11 weeks 
Follow-up 
 2 
3 to 5 months 
Follow-up  
3 
6 to 11 months 
Follow-up 
4 
12 to 23 months 
Follow-up 
5 
≥ 24 months 
N % n % 
 
n % n % n  % n % 
0 – 9 73 86.9 15 88.3 19 95 20 100 18 100 1 100 




























On initial presentation 73 women (86.9%) bled between 0 – 9 days and 11 women (13.1%) 
bled more than 10 days.  After the UAE procedure was done, at the 1st follow-up visit 17 
women presented of which 2 (11.7%) women reported to bleed more than 10 days.  At the 2nd 
follow-up visit 20 women presented of which only 1 reported to bleed more than 10 days.  At 
the 3rd, 4th and 5th visit, there were 20, 18 and 1 woman who came for follow-up visits 
respectively, of those women none of them bled more than 10 days. 
On initial presentation 43 women (51.2%) had vaginal bleeding between 5 and 9 days, with 
11 women (13.1%) bleeding for 10 or more days.  One woman bled for more than 30 days.  
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At the 1st follow-up visit post-UAE, 9 women (53%) continued to bleed for between 5 to 9 
days. No women bled beyond 15 days.   
At the 2nd follow-up visit post-UAE, there was a reduction in the duration of bleeding; 12 
women (60%) bled for 4 days or less and the women who bled for 5 to 9 days decreased by 
18%.  The percentage of women who bled for 10 to 14 days had also decreased to 5%.   
At the 3rd, 4th and 5th follow-up, no women in this study bled beyond 9 days.   
 






2 to 11 weeks 
Follow-up 
 2 
3 to 5 months 
Follow-up  
3 
6 to 11 months 
Follow-up  
4 
12 to 23 months 
Follow-up  
5 
≥ 24 months 





26 86.7 28 80 22 78.6 20 90.9 4 80 
























Patients were asked at each follow-up visit if there was any relief of the main symptom they 
experienced at initial presentation, referring to menorrhagia, pain, dyspareunia, urinary 
frequency and constipation.   
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The number of patients assessed at each follow-up visit was different, because although at 
each follow-up visit symptomatic relief was meant to be assessed it was not always specified 
by the patient at each visit, even if the patient had presented for a follow up visit, therefore 
symptomatic relief specifically was assessed in fewer than 35 patients at each follow-up visit.  
Overall symptomatic relief was predominantly experienced by most patients at follow-up, as 
demonstrated in Table 10 above, with the lowest percentage of overall symptom relief being 
78.6% at the 3rd follow up visit and the maximum percentage of overall symptom relief being 
























2 to 11 weeks 
Follow-up 
2 
3 to 5 months 
Follow-up 
3 
6 to 11 months 
Follow-up 
4 
12 to 23 months 
Follow-up 
5 
≥ 24 months 
n % n % n % n % n % n % 
 
Nil 20 27.8 2 6.1 - - 1 12.5 - - 1 100 
Pain 21 29.2 9 27.3 1 25 2 25 - - - - 
Bleeding 1 1.4 7 21.2 1 25 2 25 2 40 - - 
PV Discharge 2 2.8 12 36.4 - - 2 25 2 40 - - 
Post-Embolisation 
Syndrome 
17 23.6 - - - - - - - - - - 
Sepsis 1 1.4 - - - - 1 12.5 - - - - 
Wound Haematoma / 
Infection   
7 9.7 1 3.0 - - - - - - - - 




























0 = (-) in each cell where no numeric value present 
When assessing complications, immediately after the procedure 20 women out of the 72 that 
were seen reported no complications; at the first follow-up visit 33 women presented and 2 
had no complication; at the second follow-up visit 4 women presented but all 4 reported 
complications; at the third follow-up visit 8 women presented and 1 reported no 
complications; at the fourth follow-up visit 5 women presented and they all reported 
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complications; at the fifth follow-up visit only 1 women presented and  she had no 
complications. So a total of 24 patients over the follow up period specifically responded 
having no complications to the procedure. 
An assessment of pain post procedure was made on 33 patients over the entire follow up 
period.  Immediately after the procedure 72 women were seen and 21 women reported pain; 
at the first follow-up visit 33 women presented and 9 women reported pain; at the second 
follow-up visit 4 women presented and 1 reported to have pain; at the third follow-up visit 8 
women presented and 2 reported pain; at the fourth and fifth follow-up visits 6 women 
presented but reported complications apart from pain. 
An assessment of bleeding post procedure was made on 13 patients over the entire follow up 
period.  Immediately after the procedure 72 women were seen and 1 women reported 
bleeding; at the first follow-up visit 33 women presented and 7 women reported bleeding; at 
the second follow-up visit 4 women presented and 1 reported to have bleeding; at the third 
follow-up visit 8 women presented and 2 reported bleeding; at the fourth follow-up visit 5 
women presented and 2 reported bleeding. 
An assessment of per vaginal discharge post procedure was made on 18 patients over the 
entire follow up period.  Immediately after the procedure 72 women were seen and 2 women 
reported per vaginal discharge; at the first follow-up visit 33 women presented and 12 women 
reported per vaginal discharge; at the second follow-up visit 4 women presented and none 
reported per vaginal discharge; at the third follow-up visit 8 women presented and 2 reported 




Post embolisation syndrome was assessed immediately post procedure and reported in 17 of 
the 72 women who were assessed. It was not reported by any other women at any subsequent 
follow-up visit. 
Sepsis was reported 2 patients over the entire follow-up period.  One women had sepsis 
immediately post procedure out of the 72 that were assessed and 1 woman out of the 8 
women that presented at the third follow-up visit. 
Wound haematoma/infection was reported in 8 women over the entire follow-up period.  Of 
the 72 women assessed immediately post procedure 7 women had a wound 
haematoma/infection; 1 women reported a wound haematoma/infection at the first follow-up 
visit. 
Eight women were assessed to have “other” complications over the entire follow up period 
presenting at different follow-up visits.  
The commonest complication immediately post-UAE was pain.  Notably 27.8% of patients 
had no complications immediately post-UAE.  Post-embolisation syndrome occurred in 
23.6% of women, requiring admission after the procedure.  The least common complications 
were bleeding and sepsis.  
At the 1st follow-up visit PV discharge was highest complication.  Approximately twenty-
seven percent of women complained of persistent pain.  
At the 2nd follow-up visit pain and bleeding were equally prevalent.  Two woman experienced 
complications unrelated to UAE or fibroids, however they reported these unrelated symptoms 
at follow-up.  For example one woman had hip and thigh swelling probably related to lymph 
node damage after radiation for cervical cancer.  This woman had been treated for cervical 
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cancer stage IIa and received radiation therapy, she was in remission when she presented with 
symptomatic fibroids the following year. 
At the 3rd follow-up visit 8 patients were assessed: 2 women had pain, 2 had bleeding and 2 
complained of vaginal discharge.  
At the 4th follow-up visit 5 patients were assessed: 2 had bleeding, 2 had vaginal discharge 
and 1 had “other” complication, this was the passing of “flesh” which was found to be 
necrotic fibroid material on histology. 
At the 5th follow-up visit, 1 patient was assessed and she had no complications. 
At each follow-up visit a different number of patients presented, but within the number of 
patients that presented, only certain patients responded to some of the questions, not 
necessarily all questions. Thus the number of patients at each follow up visit differed but the 
number that responded to each specific question also differed.  The table included the patients 
who presented and responded directly to that question.  This table specifically refers to those 
women that responded to questions regarding complications. 









Table 12: Outcomes in participants after UAE procedure 
Outcomes Follow-up 
1 
2 to 11 weeks 
Follow-up 
2 
3 to 5 months 
Follow-up  
3 
6 to 11 months 
Follow-up  
4 
12 to 23 months 
Follow-up  
5 
≥ 24 months 
Number Number Number Number Number 
 
Vaginal Discharge - - - 1 1 
Amenorrhoea - 1 3 3 1 
Pregnancy - - 1 3 1 
Hysterectomy 2 - - - 1 
Myomectomy - 1 2 2 - 
Re-intervention - - - - - 
Other 1 - - 1 - 
 
0 = (-) in each cell where no numeric value present. 
Outcomes were assessed post-UAE procedure in a total of 24 patients over the 5 follow-up 
visits.  Two patients were discharged.  Eight patients became amenorrhoeic. Five patients 
became pregnant.  Three patients were referred for hysterectomy and 5 patients were referred 
for myomectomy.  No patients had re-intervention.  Two patients had “other” outcomes.  
 From the “other” outcomes, one patient was referred for infertility treatment and the second 
patient required a blood transfusion after expulsion of a submucosal fibroid that caused her to 




At each follow-up visit a different number of patients presented, but within the number of 
patients that presented, only certain patients responded to some of the questions, not 
necessarily all questions. Thus the number of patients at each follow up visit differed but the 
number that responded to each specific question also differed. The table included the patients 
who presented and responded to specific questions regarding outcomes.  The outcomes I 
defined were some of the adverse effects of the procedure, such as vaginal discharge, 
amenorrhoea, pregnancy, patients requiring further surgical interventions such as 
















5.2  ANALYSIS OF RESULTS  
Analytical statistical tests were employed to analyse the results of the data collected.  The 
Wilcoxon rank-sum test for paired non-parametric numeric variables and the paired t test was 
used.  Statistical significance was accepted where p<0.05.   
 
Table 13: Comparison of the mean height of fundus (HOF) & transverse area of 
dominant fibroid on ultrasound at presentation and at final visit and respective P values 
 Height of Fundus (cm) Area (cm2) 
At initial presentation  17.8 109.8 
At final visit 12.5 71.9 
P value <0.01 <0.01 
 
The mean HOF at presentation of women in this study was 17.8cm (SD ± 3.8) after UAE the 
final mean HOF was 12.5cm (SD ± 6.4).  This was a 5.3cm difference in the mean height of 
fundus after treatment.  P value<0.01 resulting in statistical significance. 
The formula used to calculate the transverse area of the dominant fibroid on ultrasound was  
     +      2  
The mean area of the dominant fibroid at initial presentation was 109.8cm2 (SD ± 49.4) and 
at final visit was 71.9cm2 (SD ± 35.4).  There was a mean area difference of 40.0cm2 (SD ± 
47.9).  This result is statistically significant with a P value<0.01.  This reduction in area 
indicates the substantial effect of UAE on fibroid shrinkage. 
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Ninety three women had their HOF measured at presentation and 85 women had their HOF 
measured at their final follow up visit. 
Ninety women had the transverse uterine area of the dominant fibroid measured on 
ultrasound at presentation and 53 women had the transverse uterine area measured on their 
last follow up visit. 
         
Table 14: Comparison of height of fundus (HOF) at presentation and area at 
presentation in patients with follow-up visits and those who did not follow-up with the 
respective P values 
 HOF at presentation (cm) Area at presentation (cm2) 
Follow-up 18.3 113.2 
No follow-up 16.3 105.6 
P value 0.0048 0.47 
 
The mean difference in HOF of patients who did follow-up compared to those who did not 
follow-up was 2.06cm.  This was statistically significant (P < 0.05).   
The area on initial presentation of patients who did follow-up was 113.2 cm2 (SD ± 47.4) and 
in the patients that did not follow-up was 105.6cm2 (SD ± 52.0).  The P value was not 








The mean age of the women in this study was 34.5 years, over a decade less than women in 
other studies reviewed.  In the African population symptoms present at a younger age, with 
more severe symptoms and larger fibroids.20,25Since the study population was African in the 
present study, this could account for why the mean age was lower in my study. 
Study by author  
(year published) 
Women with fibroids 
 Age Range Mean Age 
Ravina et al (1995) 34 – 49 years 44 years 
Spies et al (2001) 30 – 52 years 43 years 
Pron et al (2006) 19 – 56 years  43 years 
Walker et al (2006) 30 – 44 years 44 years 
Sasa et al (2011) - 41.7 years 
Present study(2014) 30 – 38 years (IQR) 34.5 years 
 
 
Previous pregnancy outcomes: 
In this study, 70.4% of women were nulliparous and 45.6% of women in the study had never 
conceived.  Whether the relationship between nulliparity and fibroids are causal or vice versa 





In my study adequate data was not collected on contraceptive use, only 8 women had 
information on contraceptive use so I was unable to establish an association between 
contraceptive use and the occurrence of fibroids. 
Presenting symptoms 
In most of the literature reviewed, menorrhagia is the most common presenting symptom in 
women with fibroids and is also the major indication for UAE.14,26However in my study, pain 
was the most frequent symptom (90.6%) followed by menorrhagia (85.7%). 
Passing of clots during menstruation was included as a symptom of menorrhagia in my study.  
Menorrhagia occurred between 30 to 85% in other studies17,20,22,25, correlating with the rate in 
my study.  Menorrhagia is not only the most common presenting symptom but it results in 
iron deficiency anaemia.6,12,20Dysmenorrhoea is associated with menorrhagia in most cases, 
with 62% to 83% of women reporting this symptom.20,22,25Pelvic pain and pressure symptoms 
depend on the area of fibroid growth.17Dyspareunia was recorded in 41% of women in the 
Ontario trial.20Pressure symptoms were found to be the least frequent presenting symptom in 
my study but results were variable, in other studies ranging up to 73%.   
In the Black Women’s Health Study, 55% of women were diagnosed with fibroids after 
seeking treatment for fibroid related symptoms.9Five percent of women had a combination of 
symptoms, this rate was higher in my study, with 76% of women having more than one 
symptom.  In the Ontario Uterine Fibroid Trial black women and younger women were more 
likely to report pain and bleeding.20This was similar to my study where the mean age of black 





Fibroids were located intramurally in 93.9% of women in my study in keeping with the 
Ontario trial where the largest fibroid was predominantly located intramurally on ultrasound 
or MRI imaging.14 
According to the records kept, only 33% of women had the location of the fibroids noted.  
This lack of record keeping may have been due to difficulty in determining where the fibroid 
was located or whether to classify the fibroid as intramural, submucosal or subserosal 
depending on how much of the fibroid was in which area.   
Pedunculated fibroids are a contraindication to UAE as embolisation of these fibroids can 
lead to stalk necrosis and potential detachment of the fibroid from the uterus either into the 
abdominal cavity or into the endometrial cavity and lead to complications.   
Submucosal fibroids were also excluded from my study as per the protocol at CHBAH, due 
to the risk of intracavity necrotic debris that may obstruct the cervix or become infected and 
require further intervention.  However one patient with a submucosal fibroid did have UAE 
performed but this patient was an exception.  She was discussed with the radiologist, as she 
had menorrhagia that had  required a blood transfusion on two previous occasions  and still 
had prolonged bleeding of 18 days per month.  She showed no response to medical 
management and refused surgery, so UAE was attempted as another measure to treat her. 
Haemoglobin levels 
According to the WHO classification anaemia is defined as a haemoglobin (Hb) level under 
12g/dL in a non-pregnant woman over the age of 15 years.  In my study the pre-procedural 
mean Hb was 11.1g/dL suggesting that the average woman in the study was mildly anaemic. 
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A post-procedural Hb level was not done routinely at the same interval on all patients.  In fact 
less than a third of patients had Hb levels performed, on occasion up to two years after the 
procedure, and were only taken if the patient presented for a complication of UAE or of 
fibroids or even an unrelated problem.  Thus this result is not an accurate reflection of Hb 
levels post-UAE. 
Further, the patient in my study with an Hb of 4.3g/dL, experienced a complication post-
UAE, with persistent vaginal bleeding caused by expulsion of the fibroid and on first follow-
up visit, the patient needed a blood transfusion.   
In a study in Japan with a one year follow-up, anaemia significantly decreased in just two 
months after the procedure with the mean Hb improving from 8.5 g/dL to 11.5 g/dL.23 
Although haemoglobin levels would be a good marker of response in patients with a history 
of menorrhagia and is not subjective, surprisingly only one study in the literature reviewed 
included this variable in their data collection as an indicator of reduced bleeding in the 
women studied. 
UAE procedure 
The femoral puncture site was not mentioned in the patient's notes unless double puncture 
was done.  We assumed that 91% of patients required only a single skin puncture to gain 
access.  In a study by Spies et al in 2002 the rate of women who had bilateral femoral 
puncture was 1%.24 
Duration of vaginal bleeding 
The duration of bleeding per menstrual cycle ranged mostly between 5 to 9 days in my study.  
A normal menstrual period may be between 2 to 7 days but this varies among women. By the 
second follow-up visit and every visit thereafter there was reduction in the duration of 
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bleeding, showing a response in the majority of women to UAE.  Of interest, only 16 of the 
84 women had menses for 8 or more days, however menorrhagia was a complaint among 78 
out of 91 women, so the number of days did not necessarily relate to perception of 
menorrhagia.  Rather it seems the menstrual flow was more distressing to patients.  Perhaps if 
the blood loss had been quantified, this link would be more meaningful. 
In the REST trial, the mean duration of menstrual flow decreased significantly from baseline 
to 12 months with a reduction in number of days of bleeding by 1.7 days but no statistically 
significant change in mean cycle length.16In the Ontario trial, the mean menstrual duration 
significantly reduced from 7.6 to 5.4 days.  The number of women who reported a menstrual 
duration of more than 7 days decreased from 30% to 9% subsequent to UAE. 
Symptomatic relief 
Symptomatic relief after UAE, was found to be improved in the majority of women in my 
study.  The women were questioned on each follow-up visit whether symptomatic relief had 
occurred referring to their main presenting symptom.  Reflecting on all follow-up visits, a 
minimum of 78.6% and a maximum of 90.9% women responded positively to having 
symptomatic relief.  The results of my study were slightly more encouraging than a case 
series of 400 women in which 73% to 90% reported symptomatic improvement within six 
months.15Although this was a “yes/no” response, it reflected the woman’s feeling of whether 
UAE was effective in relieving their symptoms and indirectly indicating satisfaction with the 
procedure. 
Apart from symptomatic relief, other studies assessed quality of life (QOL).That parameter 






Pain was reported as a complication in 33 out of the 100 women in my study. Twenty one 
women experienced this, not unexpectedly as an immediate complication post-procedure.  
Only 3 women experienced pain beyond 12 weeks.  As compared to other studies pain was 
the commonest complication after UAE, however isolated pain control that required 
readmission did not occur, and pain was managed routinely but without opioids. 
Vaginal discharge 
In my study 18 patients complained of vaginal discharge in the 2 years of the study.  This rate 
is unusually low compared to the literature reviewed.  Vaginal discharge is a common 
gynaecological complaint for which women may access help at a primary health care clinic.  
This could account for the low rate in my study.  Also patients with submucosal fibroids were 
excluded from my study so there should be less expulsion of fibroids experienced by my 
patients.   
Post-Embolisation Syndrome 
PES was reported in fewer than 25% of women in my study.  Recommended treatment was 
administered routinely post-procedure and on discharge possibly accounting for why the rate 
was lower than in other studies. Patients were questioned about these immediate symptoms 
on their initial follow-up 2 to 11weeks after UAE so it is unlikely that this rate is due to 






Sepsis occurred in 2 patients in my study, but it was not overwhelming sepsis and they were 
treated successfully with antibiotics only.   
In an Iranian study (2013) unspecified immune compromise was a contra-indication to UAE. 
Perhaps the concern that prompted this was a potential for higher sepsis rates after UAE in 
these individuals.26The retroviral status of patients in my study was not tested, but with a low 
rate of sepsis in my study, I do not think retroviral status would have impacted on sepsis rates 
post-UAE.  This could be investigated further. 
Wound haematoma/infection 
This a minor complication of the procedure.  In my study wound haematomas occurred in 8 
out of the 100 patients, predominantly as an immediate complication post-procedure in 7 of 
the 8 cases.  Treatment was instituted and symptoms resolved subsequently.  There was no 
trauma to the femoral artery in any of the patients who underwent UAE in my study and 
pulses were checked routinely post-procedure to ensure this. 
Other complications 
A variety of minor complications of <1% incidence have arisen from other studies but not in 
mine, such as urinary tract infections or urinary retention, drug reactions, phlebitis or thrush.  
There were no fatal or major complications in my study.  As with prospective data collected 
from two studies, one by Spies et al with 400 patients with follow-up up for a year where 
there were no deaths or permanent disabilities, and the other from the FIBROID registry with 






In my study 8% of women became amenorrhoeic.  Of the ages of women whose menses 
ceased, 6 were between 40 to 45 years and the other 2 women were both 33 years old.  These 
results were similar to those of women in the under 40 year age group referred to in the 
literature, however I would have expected the amenorrhoeic women to be in the over 45 year 
age group.21,27Thus I cannot attribute the amenorrhoea to a perimenopausal state, or related to 
UAE.  Furthermore the cause of amenorrhoea cannot be ascertained as it was not investigated 
for.  
Pregnancy 
The consensus from literature is that women must be cautious about fertility after UAE and 
that even though pregnancy is a possibility, fertility preservation and improvement cannot be 
guaranteed.  Possible complications of pregnancy are not predictable.26 
In my study, 5 women who followed up within the 2 year period conceived, however the 
success of those pregnancies was not pursued in 2 of the cases. Two women carried to term 
and 1 experienced a miscarriage.  This conception rate is higher than rates mentioned in the 
literature.  Interestingly, patients in my study were excluded if they were trying to conceive, 
however the conception rate was still higher than other studies previously mentioned.        
Re-intervention 
No patients had a repeat UAE in my study.  If there was no improvement in symptoms or size 
reduction then the patient was referred for surgical intervention.  Hysterectomies were 
performed in 3% of women and 5% of women had myomectomies.  The rate of any re-
intervention was much lower in my study, compared to studies discussed earlier, however the 
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follow-up period in my study was not as long as others in the literature, which may account 
for the lower rate of intervention.  Further the only alternative offered to my patients, in the 
event of failure of UAE or recurrence of symptoms was surgery.  In women who initially 
refused surgery and opted for UAE, this may be why the intervention rate was lower because 
these patients may have opted to tolerate symptoms instead.  Also in terms of surgical re-
intervention, dilatation and curettage with hysteroscopic resection was not offered as an 
alternative in my study.  
 
Mean Height of Fundus (HOF) & Transverse area of dominant fibroid on Ultrasound at 
presentation and at final visit  
The measurement of fundal height is less scientifically accurate and less objective than 
diameters measured on imaging, thus both assessments were made.  UAE proved to be 
effective in fibroid reduction in my study both by HOF assessment which decreased by an 
average of 5.3cm as well as area on ultrasound which decreased by 40cm2.  A statistically 
significant reduction correlates with all studies reviewed in the literature, confirming the 
efficacy of UAE.  Specific to my study compared to most other studies, area was used instead 
of volume. 
 
Height of fundus (HOF) at presentation and area at presentation in patients with follow-up 
visits and those who did not follow-up 
The mean difference in HOF of patients who did follow-up compared to those who did not 
was statistically significantly.  Thus the reason for loss of follow-up must be considered.  It is 
likely that the patients who did follow-up had larger fibroids and were more symptomatic and 
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thus were more inclined to monitor their response.  Conversely the patients who did not 
follow-up had smaller fibroids at presentation and perhaps there was a positive response after 
initial UAE so the patient felt follow-up was not necessary.  
The area on initial presentation of patients who did follow-up and those that did not, was not 
statistically significantly. This also reflects that the initial area of the fibroid did not impact 
on whether or not the women followed up or not. 
I speculated as to the reasons for loss to follow-up: 
· Patients may have had unresolved or worsening symptoms and decided to seek 
treatment elsewhere;  
· Patients may have had a negative experience with the actual UAE procedure and 
decided against returning for fear of a repeat procedure 
· Patients may have moved from the area or demised or 
· They may have experienced adequate symptom relief not requiring further treatment 
Patient information and counselling at initial consultation was extensive, so lack of 
knowledge should not have been a reason as to why patients defaulted follow-up. 
Each study reviewed had different patient selection criteria and contraindications for UAE, 
most were in keeping with the inclusion and exclusion criteria in my study, apart from the 
following criteria.  In my study patients who wanted to retain fertility were not offered UAE, 
in keeping with ACOG and RCOG guidelines, however some studies have offered UAE after 
thorough counselling and informed consent allowed for UAE in patients who wished to 
conceive.  Useful information has been gathered from these studies, such as the Ontario trial, 
creating a broader applicability.14   
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Large fibroid size was also a contraindication in some studies, such as a uterus larger than 20 
weeks in a Japanese study or larger than 24 weeks in Spies et al study, however in studies 
such as mine, where initial fibroid size or height of fundus was not an exclusion criteria, 
positive results were noted.14,23,24 
Although number of days admitted would have been a useful indicator of immediate 
complications and recovery time in my study, it could not be determined due to lack of 
details in patient records.  Patients were also not asked about the number of days of 
absenteeism from work or return to normal activities.  These variables could have been used 
as indicators for recovery.    
Failure in symptomatic relief occurs between 4 to 21%, this could be due to misdiagnosis.  In 
our study only ultrasound was performed, whereas MRI would have been more beneficial to 
identify other benign conditions like adenomyosis or rarely leiomyosarcoma in less than 1%.  
Despite favourable outcomes of UAE it is still not routinely offered and used widely both 
locally and internationally. Perhaps if people had more awareness of this procedure and it had 
more publicity it would attract wider use.   
A study in Netherlands, involving patients, radiologists and gynaecologists, identified factors 
which either facilitate or restrict the implementation of UAE.  Restricting factors and 
recommendations were assessed, from perspectives of each group. Obstacles identified were 
the lack of knowledge about UAE, the absence of a multidisciplinary protocol and the 
absence of UAE as a treatment option in the Dutch National guideline on the management of 





7.  LIMITATIONS 
In my study comparisons were not made to other treatment modalities. 
The study may have been prone to selection bias because referrals to the UAE clinic were by 
specialist gynaecologists and registrars from the general gynaecology out-patients 
departments.  If the criteria for referral was not known or if registrars rotating through 
CHBAH during the course of their training, did not know about the clinic then eligible 
women would not have been referred. 
Although follow-up monitoring was standardised and done by the same specialist 
gynaecologist, the actual UAE procedure was done by radiology registrars with different 
levels of experience and training, therefore the same level of success may not be achieved in 
each case. 
No data was collected on whether the women were smokers or not.  BMI was not ascertained. 
A minimal account of patient’s contraception history was obtained. 
A detailed menstrual history, beyond duration of bleeding and menorrhagia, was not sought. 
In my study, only ultrasound measurements of the dominant fibroid were used, as MRI was 
not a feasible option.  This could have resulted in less accurate measurements of the fibroids 
or even misdiagnosis in certain cases, which may account for treatment failure. 
My study did not address the patient satisfaction and impact on quality of life.  Time taken 
off work for fibroid-related reasons was as high as 40% in a year where often women were 
absent from work around the time of their menstrual period.20Should symptoms be resolved 
then functionality in the workplace would also be improved. 
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Follow-up in terms of fertility beyond the study period was not assessed.  Also patients who 
wanted to retain fertility were excluded from the study.  If a patient did conceive post-UAE 
the outcome of pregnancy was not established, thus success of pregnancies was uncertain. 
FSH and AMH levels prior to and post-procedure were not taken, thus premature ovarian 
failure could not definitively be diagnosed. 
Many patients defaulted follow-up visits.  Data obtained on symptom relief in some patients 
is not detailed as to which symptom was relieved.  Information was often missing regarding 
the actual UAE procedure.  Thus there are many gaps in the data due to lack of information 
obtained or documented at each visit.  As a result of missing information accurate assessment 
of certain results could not be made. 
Follow up visits were variable among the patients and not maintained consistently from the 
first visit till the last/5th follow-up visit.  At each follow-up visit there were a different 
number of patients that presented but also within the number of patients that presented, not all 
women responded to every question, so some may have details regarding their symptoms at 
follow up but may not have elaborated if there were any complications for example.   
Loss to follow is one of the difficulties with studies conducted in an operational setting.  The 
difference in the HOF in the group that was followed up compared to those lost to follow up 







8.  CONCLUSION 
With symptomatic fibroids that occur more commonly in younger African women with more 
severe symptoms that impact on quality of life and have a high disease burden, treatment is 
sought that is an alternative to invasive surgery and conserves the uterus, yet is effective and 
safe.  Despite the discomfort and inconvenience women experience preserving their uteri, 
they are still seeking alternatives to hysterectomy.20The benefits aside from fibroid size 
reduction, are that it is potentially an outpatient procedure with a quick recovery time and a 
less complications.13,20,28Published data is indicative that it is effective in controlling 
symptoms caused by fibroids.17,20It is a low risk procedure with little variability in short term 
outcome based on either demographics or practice settings. 
There were only minor complications, no major complications or fatalities.  However due to 
loss of follow up long term outcomes cannot be commented on.  There should be ongoing 
surveillance of women who have undergone the procedure. 
In appreciation of the results found in my study, the subsequent step would be for these 
results to have an impact on patients, gynaecologists and interventional radiologists so that 
UAE can be better implemented and more patients can be referred to the UAE clinic at 
CHBAH.  Similar strategies as found in the Netherlands study could assist in publicising 
UAE and its efficacy so that there is more awareness of the procedure and thus more 
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APPENDIX A -  DATA SHEET  








Presenting Symptoms and History 
Contraception  (  yes  /  no  /  unknown  )                                                                                                                                                                                                                              
Bleeding 
Flow  (days) :                                                                                                                                  
Clots:   (  yes   /  no  ) 
Pain   (  yes   /  no  ) 
Dyspareunia  (  yes   /  no  ) 
Pressure symptoms                                                                                                                 
Frequency (  yes   /  no  ) 
Constipation                     (  yes   /  no  ) 
   
 
Examination 










Measurement of largest fibroid 
Diameter 1 in cm     Diameter 2 in cm 
 
Haemoglobin level 
Pre-procedure      Post-procedure 
 
Puncture 
Single   1     Double 2 
UAE procedure 
Success     1                  Failure  2                                                                                                          
No of days admitted in hospital : 
 
Complications (key to be used below) 
Nil      0                                                                          
Persistent pain     1                                                       
Bleeding     2                                                                                                      
PV discharge     3                                                                                                        
Post-Embolisation Syndrome   4                                                                                 
Sepsis      5                                                                                          
Haematoma/Infection at wound site  6 
Other      7 
 
Outcomes  (key to be used below) 
Discharge    0 
Amenorrhoea    1 
Pregnancy   2 
Hysterectomy    3                                     
Myomectomy    4                                                                                                               
75 
 
Re-intervention  5                                                                                                                                                           
Other    6 
 
Follow-up at 2 weeks - 11 weeks: 
Symptom relief : (  yes   /  no  ) 
Flow (days) : 
Complications  : 
Outcomes : 
 
Follow-up 3 months – 5 months: 
Symptom relief : (  yes   /  no  ) 
Flow (days) : 
HOF : 
Fibroid size :  shrinkage  /  unchanged  /  enlarged 
Diameter 1 in cm :     Diameter 2 in cm : 
Complications  : 
Outcomes : 
 
Follow-up at 6 months – 11 months: 
Symptom relief : (  yes   /  no  ) 
Flow (days) : 
 
HOF :  
Fibroid size :  shrinkage  /  unchanged  /  enlarged        
Diameter 1 in cm :     Diameter 2 in cm : 





Follow-up at 12 months – 23 months  
Symptom relief : (  yes   /  no  ) 
Flow (days) : 
 
HOF :  
Fibroid size :  shrinkage  /  unchanged  /  enlarged 
Diameter 1 in cm :     Diameter 2 in cm : 





Follow-up at 24 months or more 
Symptom relief : (  yes   /  no  ) 
Flow (days) : 
 
HOF :  
Fibroid size :  shrinkage  /  unchanged  /  enlarged 
Diameter 1 in cm :     Diameter 2 in cm : 
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